The global adrenogenital syndrome treatment market is poised for substantial growth, with an expected market value of USD 12.81 billion in 2023. This market is projected to expand at a compound annual growth rate (CAGR) of 5.6%, reaching a forecast value of USD 22.08 billion by 2033. The surge in market growth is driven by advances in natural treatments, minimally invasive surgeries, and the introduction of new therapies.
A significant factor propelling the growth of the AGS treatment market is the establishment of newborn screening programs, particularly in Austria, where programs have been set up to detect severe forms of AGS early. These efforts ensure affected children receive appropriate treatments to prevent life-threatening salt-wasting crises. Among these treatments is swap therapy, administered as part of newborn screening protocols.
In addition, the increasing recognition of milder, non-classical forms of AGS, which often remain undiagnosed due to their delayed onset and milder symptoms, is fueling market growth. Many of these cases go unnoticed for years, further emphasizing the need for enhanced awareness and treatment options.
Surgical interventions, such as correcting abnormal genital appearances, are also gaining traction in the market, contributing to the overall growth. Hormonal therapy, a cornerstone in AGS management, helps replace hormones that are not produced by the adrenal glands. Corticosteroids or hydrocortisone are often administered daily to patients, helping normalize androgen production.
With a higher prevalence of AGS among children and infants, the market is expected to see a continued upward trajectory. Infants diagnosed with AGS are typically treated with hormone injections in the early stages, transitioning to oral hormone treatments after 18 months. The condition’s early detection and treatment have significantly improved survival rates, with patients who receive treatment often leading normal lives. In contrast, untreated infants have a survival rate of less than six weeks.
As awareness and treatments for AGS continue to evolve, the global market for AGS treatment is set to expand rapidly, improving outcomes for affected individuals worldwide.
Key Takeaways from the Market Study:
- Globally, the adrenogenital syndrome treatment market is expected to reach USD 12.81 billion by 2023.
- Retail pharmacies for adrenogenital syndrome treatment are expected to accumulate 24% market share.
- The glucocorticoid drugs are expected to grow at a CAGR of 4.3% of during the forecast period.
- Adrenogenital syndrome treatment in North America expanded with a market share of 22% during the forecast period.
- Over the next few years, it is expected that the oral drugs market will account for 16% of sales.
“New drug developments and government-funded research studies will further accelerate growth in the adrenogenital syndrome treatment market.” comments a Future Market Insights analyst.
Growing Market Interest: Explore Comprehensive Insights and Trends with Our Detailed Report!
Competitive Landscape:
As more companies focus on the development of innovative diagnostic techniques, which will likely see many firms expand their product lines, acquire other firms, or merge their companies together in the near future, as a result of the fact that many will be focusing on the development of new diagnostic techniques in the near future.
- BridgeBio Pharma, Inc., is conducting Phase 1/2 clinical trials for BBP-631 a novel gene therapy based on adeno-associated virus (AAV) 5 for the treatment of classic congenital adrenal hyperplasia (CAH), a commercially stage biopharmaceutical company that specializes in genetic diseases and cancers, its first patient has been dosed. Approximately 75,000 cases of CAH are estimated to exist in the United States and the European Union, making it one of the most prevalent genetic diseases.
- CARES Foundation hosted its 5th Annual CAH Awareness Walk to support those suffering from Congenital Adrenal Hyperplasia. Classical CAH is a severe form of CAH that can be life-threatening. Over 75 percent of those suffering from classical CAH lack aldosterone, an additional adrenal hormone essential for regulating the body’s fluid volume, sodium, and potassium, among other functions, to stabilize the heart. There is less severity in the non-classical form. Affected individuals can live a normal life with adequate care and medication for CAH.
Key Companies Profiled:
Crystal Pharma; Monarch Pharmaceuticals, Inc.; Jubilant Cadista Pharmaceuticals Inc.; Pfizer CentreOne; Healthkey Lifescience Pvt. Ltd.; Zydus Pharmaceuticals; Praxgen Pharmaceuticals; Sandoz; Vintage Labs; Actavis, Inc.
Key Segments Profiled in the Adrenogenital Syndrome Treatment Market Industry Survey:
By Drug Type:
- Mineralocorticoids
- Glucocorticoids
By Route of Administration:
- Oral
- Parenteral
- Intravenous
- Inhaled
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
